PYRIDAZINE COMPOUNDS FOR INHIBITION OF NAV1.8
Patent Information
- Application Number
- DE602019076972
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-07-09
- Filing Date
- 2019-07-09
- Publication Date
- 2025-10-15
- Estimated Expiration
- 2039-07-09
AI Technical Summary
Current treatments for chronic and acute pain, such as steroidal and nonsteroidal anti-inflammatory drugs, amine reuptake inhibitors, and opioids, have limitations, and selective inhibitors for voltage-gated sodium channels, particularly Na v 1.7 and Na v 1.8, have shown limited efficacy in clinical trials, while Na v 1.8 inhibitors face challenges with selectivity and pharmacokinetics.
Development of pyridazine compounds that selectively inhibit Na v 1.8 sodium channels, which are administered to modulate or inhibit the channel activity, thereby treating conditions associated with increased Na v 1.8 expression or activity, including pain, neurological disorders, and psychiatric diseases.
The pyridazine compounds effectively inhibit Na v 1.8 channels, providing therapeutic benefits for conditions like inflammatory and neuropathic pain, multiple sclerosis, and autism, with potential for improved selectivity and pharmacokinetic profiles compared to existing inhibitors.